What is the Medical Research Commercialisation Fund?

The Medical Research Commercialisation Fund provides up to $2 M is available to support the development and commercialisation of early-stage medical research discoveries.



The Medical Research Commercialisation Fund is an innovative investment collaboration which invests in life science opportunities from its member medical research institutes and their associated hospitals throughout Australia.

The Medical Research Commercialisation Fund provides its Members with a range of benefits, including:

  • An early-stage fund dedicated to supporting the development and commercialisation of early-stage medical technologies;
  • Access to risk-tolerant investment capital to support the development of promising technologies,
  • Involvement in and exposure to the Investment Review process; and
  • The investors gain access to promising technologies emanating from the Member Institutes.



Established in 2007, investment funding from the Medical Research Commercialisation Fund (MRCF) is available to promising opportunities from its 50 member institutes.

The MRCF’s investors are AustralianSuper, Statewide Super, HESTA, HOSTPLUS and the Australian Government under its IIF program. The MRCF acknowledges support from the State Governments of Victoria, New South Wales, Western Australia, Queensland and South Australia.

MRCF is managed by Brandon Capital Partners, a life science fund manager, and each member institute nominates a representative to the Investment Review Committee (IRC). The MRCF has received $30 million in funding from superannuation funds and $20 million from the Federal Government’s IIF program.



he Medical Research Commercialisation Fund provides funding of $200,000 to $2 million for any one project, investing up to $1 million on its own, and reserves the second $1 million for further rounds of investment made alongside co-investors. It also provides financial and strategic management assistance.



Eligible applicants include medical research institutes. The Medical Research Commercialisation Fund invests exclusively in opportunities from its member institutes.

Eligible activities include opportunities with milestone-based development programs requiring smaller first round financial commitments to generate further exemplification of the technology.



Application for the Medical Research Commercialisation Fund are open on an ongoing basis.


Media Release

Brandon Capital has closed the first tranche of funding for its new $250 million biotech fund, with the venture capital firm’s earlier funds successfully outperforming the S&P/ASX 200 for the past 10 years.
Brandon Capital managing director Dr Chris Nave told The Australian Financial Review it still had some capital remaining in its $200 million MRCF 3, but this was reserved for growth capital to support the 16 companies it had already backed through that fund.
While its newest fund has been named MRCF 5, there is no MRCF 4, with its fourth fund considered to be the $230 million in capital it is managing as part of the government’s $500 million Biomedical Translation Fund.
Having launched in 2007 with a $30 million fund, Brandon Capital is one of the older VC funds on the block and it now has more than $700 million million in capital under management.


More Information